Business
Enovis Announces First Quarter 2025 Results
Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter end
About this update from Enovis Corporation
[{"type":"image","alt":"Enovis Corporation","displaySize":"","headline":null,"caption":"Enovis Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qc6jvQoTNwKdaM8z5d_s_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92","width":300,"height":73}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":131,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"First-quarter Reconstructive sales grew 11% year-over-year on a reported basis ","length":78,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":78,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Appointed Damien McDonald as CEO, effective May 12th, 2025","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":58,"olType":false},{"type":"text","content":"Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.","length":365,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Results","length":36,"tagName":"p"},{"type":"text","content":"Enovis’ first-quarter net sales of $559 million grew 8% on a reported basis and 9% (+10% xFX) on a comparable basis from the same quarter in 2024. First quarter results reflect continued execution in P&R, a rebound in growth in Recon, and accelerating momentum in new product introductions. Compared to the same quarter in 2024, net sales in Recon grew 11% on a reported and comparable basis (+13% xFX), and P&R grew 5% on a reported basis and 7% (+8% xFX) on a comparable growth basis.","length":494,"tagName":"p"},{"type":"text","content":"Enovis also reported first-quarter net loss from cont...